Ascendis Pharma AS (ASND)vsRoyalty Pharma Plc (RPRX)
ASND
Ascendis Pharma AS
$210.45
-3.83%
HEALTHCARE · Cap: $13.32B
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 182% more annual revenue ($2.44B vs $865.78M). ASND leads profitability with a 57.3% profit margin vs 33.9%. ASND trades at a lower P/E of 24.7x. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ASND
Buy55
out of 100
Grade: C
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASND.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 104 in profit
Keeps 57 of every $100 in revenue as profit
Revenue surging 144.3% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Elevated debt levels
Weak financial health signals
Trading at 23.3x book value
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 57.3% and operating margin at 10.1%. Revenue growth of 144.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ASND
The primary concerns for ASND are EPS Growth, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.84 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ASND profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
ASND carries more volatility with a beta of 0.48 — expect wider price swings.
ASND is growing revenue faster at 144.3% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 55/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?